cyclopentane has been researched along with rhc 3659 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunner, HR; Nussberger, J; Waeber, B | 1 |
| Biollaz, J; Brunner, HR; Burnier, M; Gavras, H; Turini, GA | 1 |
| Brunner, HR; Burnier, M; Gavras, H; Kruithof, D; Porchet, M; Turini, GA; Vukovich, RA | 1 |
| Loev, B; Mann, WS; Smith, RD; Suh, JT; Wolf, PS | 1 |
| Dongmin, C; Fei, L; Huimei, H | 1 |
1 review(s) available for cyclopentane and rhc 3659
| Article | Year |
|---|---|
The present molecules of converting enzyme inhibitors.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Bridged Bicyclo Compounds; Captopril; Cilazapril; Cyclopentanes; Dipeptides; Enalapril; Humans; Indoles; Lisinopril; Perindopril; Pyridazines; Ramipril; Renin-Angiotensin System | 1985 |
4 other study(ies) available for cyclopentane and rhc 3659
| Article | Year |
|---|---|
Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril.
Topics: Adult; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Cyclopentanes; Dipeptides; Dose-Response Relationship, Drug; Enalapril; Humans; Proline | 1982 |
RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cyclopentanes; Dose-Response Relationship, Drug; Humans; Male; Renin; Time Factors | 1981 |
Angiotensin-converting enzyme inhibitory and antihypertensive activities of pivalopril (RHC 3659-(S)).
Topics: Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Cyclopentanes; Dogs; Dose-Response Relationship, Drug; Hypertension; Kinetics; Male; Rats; Rats, Inbred Strains; Sodium | 1984 |
Pivalopril improves anti-cancer efficiency of cDDP in breast cancer through inhibiting proliferation, angiogenesis and metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Cyclopentanes; Female; Humans; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic | 2020 |